SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206421422> ?p ?o ?g. }

Showing items 1 to 91 of 91 with 100 items per page.

W3206421422 endingPage "A1881" @default.
W3206421422 startingPage "A1877" @default.
W3206421422 abstract "TOPIC: Obstructive Lung Diseases TYPE: Original Investigations PURPOSE: Chronic oral corticosteroid (OCS) treatment improves asthma control but is associated with severe side effects. Dupilumab (DPL), a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4/-13, key and central drivers of type 2 inflammation in multiple diseases. In the phase 3 VENTURE study (NCT02528214), add-on DPL 300 mg every two weeks (q2w) vs placebo (PBO) significantly reduced daily OCS dose and severe asthma exacerbation rate, improving pre-bronchodilator FEV1 in patients with OCS-dependent, severe asthma. TRAVERSE (NCT02134028), a single-arm, open-label, extension study, evaluated long-term safety, tolerability, and efficacy of add-on DPL in patients who had completed a DPL study. Overall, 2,182 (96%) patients completed TRAVERSE to Week (Wk) 48 and 1,240 (54%) to Wk 96, with a cumulative study duration of 3,507 patient-years. This post hoc analysis assessed long-term improvements in lung function in patients with OCS-dependent asthma from VENTURE who enrolled in TRAVERSE. METHODS: Mean change from baseline (BL) of the VENTURE study in lung function was assessed at Wk 0, 2, and 48 in patients treated with DPL or PBO for 24 Wks in VENTURE who then enrolled in TRAVERSE and received DPL 300 mg q2w for up to 96 Wks. Treatment duration was amended from 96 to 48 Wks for some patients. RESULTS: Mean reductions in OCS dose from parent study BL (PSBL) at Wk 0 (end of VENTURE/start of TRAVERSE) were 74.2% and 45.8% in the DPL-DPL (n=90) and PBO-DPL (n=97) groups. In DPL-DPL–treated patients, FEV1 improvements in VENTURE were sustained in TRAVERSE (PSBL [SD]: 1.53 [0.50] L; mean change [SD] from PSBL: 0.29 [0.46], 0.28 [0.48], and 0.33 [0.53] L at Wk 0, 2, and 48). Improvements persisted for FEF25–75% (PSBL [SD]: 0.87 [0.49] L/s; mean change [SD] from PSBL: 0.23 [0.49], 0.23 [0.57], and 0.29 [0.66] L/s at Wk 0, 2, and 48) and FVC (PSBL [SD]: 2.59 [0.73] L; mean change [SD] from PSBL: 0.34 [0.58], 0.32 [0.48], and 0.38 [0.56]L at Wk 0, 2, and 48). In PBO-DPL–treated patients starting DPL at Wk 0, rapid improvement in lung function occurred by Wk 2 and continued through Wk 48 in FEV1 (PSBL [SD]: 1.62 [0.62] L; mean change [SD] from PSBL: −0.01 [0.50], 0.25 [0.49], and 0.31 [0.50] L at Wk 0, 2, and 48), FEF25-75% (PSBL [SD]: 0.93 [0.57] L/s; mean change [SD] from PSBL: 0.04 [0.52], 0.26 [0.56], and 0.34 [0.56] L/s at Wk 0, 2, and 48), and forced vital capacity (FVC) (PSBL [SD]: 2.74 [0.80] L; mean change [SD] from PSBL: −0.04 [0.52], 0.23 [0.50], and 0.29 [0.56] L at Wk 0, 2, and 48). There were minimal changes in the FEV1/FVC ratio, consistent with balanced improvement in FEV1 and FVC. CONCLUSIONS: Dupilumab demonstrated sustained lung function improvements in the DPL-DPL–treated group, and rapid, sustained improvements in the PBO-DPL group. CLINICAL IMPLICATIONS: Dupilumab shows long-term lung function improvements in OCS-dependent severe asthma patients who enrolled in TRAVERSE. DISCLOSURES: Employee relationship with Regeneron Pharmaceuticals Please note: Since 01/04/2016 Added 04/30/2021 by Nikhil Amin, source=Web Response, value=Salary Author relationship with Elsevier Please note: $1-$1000 by Mario Castro, source=Web Response, value=Royalty Removed 04/30/2021 by Mario Castro, source=Web Response Principal Investigator relationship with Novartis Please note: $20001 - $100000 by Mario Castro, source=Web Response, value=Grant/Research Support Removed 04/30/2021 by Mario Castro, source=Web Response Consultant relationship with Novartis Please note: $5001 - $20000 by Mario Castro, source=Web Response, value=Consulting fee Removed 04/30/2021 by Mario Castro, source=Web Response Principal Investigator relationship with AstraZeneca Please note: $20001 - $100000 by Mario Castro, source=Web Response, value=Grant/Research Support Removed 04/30/2021 by Mario Castro, source=Web Response Speaker/Speaker's Bureau relationship with AstraZeneca Please note: $5001 - $20000 by Mario Castro, source=Web Response, value=Honoraria Removed 04/30/2021 by Mario Castro, source=Web Response Principal Investigator relationship with ALA Please note: $20001 - $100000 by Mario Castro, source=Web Response, value=Grant/Research Support Removed 04/30/2021 by Mario Castro, source=Web Response Principal Investigator relationship with Sanofi-Aventis Please note: $20001 - $100000 by Mario Castro, source=Web Response, value=Grant/Research Support Removed 04/30/2021 by Mario Castro, source=Web Response Consultant relationship with Sanofi-Aventis Please note: $5001 - $20000 by Mario Castro, source=Web Response, value=Consulting fee Removed 04/30/2021 by Mario Castro, source=Web Response Speaker/Speaker's Bureau relationship with Sanofi-Aventis Please note: $5001 - $20000 by Mario Castro, source=Web Response, value=Honoraria Removed 04/30/2021 by Mario Castro, source=Web Response Speaker/Speaker's Bureau relationship with Regeneron Please note: $5001 - $20000 by Mario Castro, source=Web Response, value=Honoraria Removed 04/30/2021 by Mario Castro, source=Web Response Advisory Committee Member relationship with PCORI Please note: $5001 - $20000 Added 04/30/2021 by Mario Castro, source=Web Response, value=Honoraria Removed 04/30/2021 by Mario Castro, source=Web Response Consultant relationship with Teva Please note: $5001 - $20000 by Mario Castro, source=Web Response, value=Consulting fee Removed 04/30/2021 by Mario Castro, source=Web Response Principal Investigator relationship with GSK Please note: $20001 - $100000 by Mario Castro, source=Web Response, value=Grant/Research Support Removed 04/30/2021 by Mario Castro, source=Web Response Speaker/Speaker's Bureau relationship with GSK Please note: $5001 - $20000 by Mario Castro, source=Web Response, value=Honoraria Removed 04/30/2021 by Mario Castro, source=Web Response Speaker/Speaker's Bureau relationship with Genentech Please note: $5001 - $20000 by Mario Castro, source=Web Response, value=Honoraria Removed 04/30/2021 by Mario Castro, source=Web Response Consultant relationship with Genentech Please note: $5001 - $20000 by Mario Castro, source=Web Response, value=Consulting fee Removed 04/30/2021 by Mario Castro, source=Web Response Principal Investigator relationship with Shionogi Please note: $20001 - $100000 by Mario Castro, source=Web Response, value=Grant/Research Support Removed 04/30/2021 by Mario Castro, source=Web Response Principal Investigator relationship with NIH Please note: >$100000 by Mario Castro, source=Web Response, value=Grant/Research Support Removed 04/30/2021 by Mario Castro, source=Web Response Principal Investigator relationship with PCORI Please note: >$100000 by Mario Castro, source=Web Response, value=Grant/Research Support Removed 04/30/2021 by Mario Castro, source=Web Response Principal Investigator relationship with PCORI Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Study Funding Principal Investigator relationship with AstraZeneca Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Study Funding Speaker/Speaker's Bureau relationship with AstraZeneca Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Honoraria Principal Investigator relationship with Novartis Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Study Funding Consultant relationship with Novartis Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Consulting fee Principal Investigator relationship with GSK Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Study Funding Speaker/Speaker's Bureau relationship with GSK Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Honoraria Principal Investigator relationship with Sanofi-Aventis Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Study Funding Speaker/Speaker's Bureau relationship with Sanofi-Aventis Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Honoraria Consultant relationship with Sanofi-Aventis Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Consulting fee Consultant relationship with Ongoing Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Consulting fee Speaker/Speaker's Bureau relationship with Teva Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Genentech Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Honoraria Consultant relationship with Genentech Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Consulting fee Speaker/Speaker's Bureau relationship with Regeneron Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Honoraria Author relationship with Elsevier Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Royalty Principal Investigator relationship with Shionogi Please note: Ongoing Added 04/30/2021 by Mario Castro, source=Web Response, value=Study Funding Advisory Committee Member relationship with AstraZeneca Please note: $1001 - $5000 by Jonathan Corren, source=Web Response, value=Honoraria Speaker/Speaker's relationship with AstraZeneca Please note: $5001 - $20000 by Jonathan Corren, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Genetech Please note: $5001 - $20000 by Jonathan Corren, source=Web Response, value=Honoraria Research funds relationship with Genetech Please note: $5001 - $20000 by Jonathan Corren, source=Web Response, value=Grant/Research Support Research funds relationship with AstraZeneca Please note: $5001 - $20000 by Jonathan Corren, source=Web Response, value=Grant/Research Support Board Member relationship with Novartis Please note: $1001 - $5000 by Jonathan Corren, source=Web Response, value=Honoraria Research funds relationship with Novartis Please note: $5001 - $20000 by Jonathan Corren, source=Web Response, value=Grant/Research Support Speaker/Speaker's Bureau relationship with Regeneron/Sanofi Please note: $5001 - $20000 by Jonathan Corren, source=Web Response, value=Honoraria Board Member relationship with Regeneron/Sanofi Please note: $1001 - $5000 by Jonathan Corren, source=Web Response, value=Honoraria Research funds relationship with Regeneron/Sanofi Please note: $5001 - $20000 by Jonathan Corren, source=Web Response, value=Grant/Research Support Employee relationship with Regeneron Pharmaceuticals Please note: >$100000 Added 04/29/2021 by Yamo Deniz, source=Web Response, value=Stock and Options Employee relationship with Sanofi Please note: $20001 - $100000 by Michel Djandji, source=Web Response, value=Salary Employee relationship with Regeneron Pharmaceuticals Please note: 2010-2016, 2020-2021 Added 05/05/2021 by Rebecca Gall, source=Web Response, value=Salary Employee relationship with Sanofi Genzyme Please note: 2018-2021 Added 05/04/2021 by Megan Hardin, source=Web Response, value=Salary Employee relationship with Sanofi-Genzyme Please note: 2019 to present Added 04/30/2021 by Juby Jacob-Nara, source=Web Response, value=Salary Employee relationship with Sanofi Please note: current employee Added 04/30/2021 by Elizabeth Laws, source=Admin input, value=Salary Consultant relationship with Veracyte Please note: $5001 - $20000 by David Lederer, source=Web Response, value=Consulting fee Removed 04/30/2021 by David Lederer, source=Web Response Consultant relationship with Roche Please note: $1-$1000 by David Lederer, source=Web Response, value=Consulting fee Removed 04/30/2021 by David Lederer, source=Web Response Advisory Committee Member relationship with Boehringer-Ingelheim Please note: $1-$1000 by David Lederer, source=Web Response, value=0 Removed 04/30/2021 by David Lederer, source=Web Response Consultant relationship with Galapagos Please note: $1-$1000 by David Lederer, source=Web Response, value=Consulting fee Removed 04/30/2021 by David Lederer, source=Web Response Advisory Committee Member relationship with Fibrogen Please note: $1-$1000 by David Lederer, source=Web Response, value=Consulting fee Removed 04/30/2021 by David Lederer, source=Web Response Advisory Committee Member relationship with Global Blood Therapeutics Please note: $1001 - $5000 by David Lederer, source=Web Response, value=Consulting fee Removed 04/30/2021 by David Lederer, source=Web Response Consultant relationship with Galecto Please note: $1-$1000 by David Lederer, source=Web Response, value=Travel Removed 04/30/2021 by David Lederer, source=Web Response Advisory Committee Member relationship with Sanofi Genzyme Please note: $5001 - $20000 by David Lederer, source=Web Response, value=Consulting fee Removed 04/30/2021 by David Lederer, source=Web Response Employee relationship with Regeneron Please note: July 2019 to current Added 04/30/2021 by David Lederer, source=Web Response, value=Salary Stock/Stock options relationship with Regeneron Please note: July 2019 to current Added 04/30/2021 by David Lederer, source=Web Response, value=Stock/Stock options Employee relationship with Sanofi Please note: 2000-2021 Added 04/30/2021 by Leda Mannent, source=Web Response, value=Salary Employee relationship with Sanofi Please note: 09/02/2014 Added 05/04/2021 by Xuezhou Mao, source=Web Response, value=Salary Employee relationship with Regeneron Pharmaceuticals Inc. Please note: >$100000 by Benjamin Ortiz, source=Web Response, value=Salary Advisory Committee Member relationship with Astrazeneca, Chiesi, GSK Please note: Present Added 04/30/2021 by Alberto Papi, source=Web Response, value=Honoraria Advisory Committee Member relationship with edmondpharma, zambon, sanofi, Please note: 2020 Added 04/30/2021 by Alberto Papi, source=Web Response, value=Honoraria Removed 04/30/2021 by Alberto Papi, source=Web Response Speaker/Speaker's Bureau relationship with AZ, GSK, Chiesi, Novartis, BI, Sanofi, Zambon, Mundipharma Please note: present Added 04/30/2021 by Alberto Papi, source=Web Response, value=Honoraria Removed 04/30/2021 by Alberto Papi, source=Web Response Speaker/Speaker's Bureau relationship with TEVA, Menarini, MSD, Elpen Pharmaceuticals Please note: 2019 Added 04/30/2021 by Alberto Papi, source=Web Response, value=Honoraria, travel expenses rei Removed 04/30/2021 by Alberto Papi, source=Web Response Speaker/Speaker's Bureau relationship with TEVA, Menarini, MSD, Elpen Pharmaceuticals Please note: 2019 Added 04/30/2021 by Alberto Papi, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with TEVA, Menarini, MSD, Elpen Pharmaceuticals Please note: 2019 Added 04/30/2021 by Alberto Papi, source=Web Response, value=Travel Speaker/Speaker's Bureau relationship with Edmondpharma Please note: 2020 Added 04/30/2021 by Alberto Papi, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with AZ, GSK, Chiesi, Novartis, BI, Sanofi, Zambon, Mundipharma Please note: Present Added 04/30/2021 by Alberto Papi, source=Web Response, value=Honoraria Grant relationship with Boehringer Ingelheim, Sanofi Please note: Present Added 04/30/2021 by Alberto Papi, source=Web Response, value=Grant/Research Support Advisory Committee Member relationship with GSK Please note: $1001 - $5000 by Ian Pavord, source=Web Response, value=Consulting fee Employee relationship with Sanofi Pharmaceutical Please note: >$100000 by Paul Rowe, source=Web Response, value=Salarystock holder relationship with Regeneron Please note: since 2016 Added 05/10/2021 by Marcella Ruddy, source=Web Response, value=Salary Employee relationship with Regeneron Please note: March 2016 to presen Added 05/10/2021 by Marcella Ruddy, source=Web Response, value=Salary Speaker/Speaker's Bureau relationship with Boellringer Ingelheim, DaiichiSankyo, Astellas Please note: 2019-2020 Added 05/05/2021 by Yuji Tohda, source=Web Response, value=speaker fee Speaker/Speaker's Bureau relationship with Kyorin Pharmaceutical, Teijin Pharma, MeijiSeika pharma Please note: 2019-2020 Added 05/05/2021 by Yuji Tohda, source=Web Response, value=speaker fee" @default.
W3206421422 created "2021-10-25" @default.
W3206421422 creator A5006031044 @default.
W3206421422 creator A5017155583 @default.
W3206421422 creator A5017711682 @default.
W3206421422 creator A5021417774 @default.
W3206421422 creator A5024338340 @default.
W3206421422 creator A5029849168 @default.
W3206421422 creator A5030660777 @default.
W3206421422 creator A5037227971 @default.
W3206421422 creator A5039293124 @default.
W3206421422 creator A5045980264 @default.
W3206421422 creator A5050993312 @default.
W3206421422 creator A5052012397 @default.
W3206421422 creator A5058683482 @default.
W3206421422 creator A5059328493 @default.
W3206421422 creator A5060153507 @default.
W3206421422 creator A5072622243 @default.
W3206421422 creator A5075306675 @default.
W3206421422 creator A5078489750 @default.
W3206421422 date "2021-10-01" @default.
W3206421422 modified "2023-09-25" @default.
W3206421422 title "EFFECT OF DUPILUMAB ON LUNG FUNCTION PARAMETERS IN ORAL CORTICOSTEROID-DEPENDENT PATIENTS WITH ASTHMA ENROLLED IN LIBERTY ASTHMA TRAVERSE" @default.
W3206421422 doi "https://doi.org/10.1016/j.chest.2021.07.1675" @default.
W3206421422 hasPublicationYear "2021" @default.
W3206421422 type Work @default.
W3206421422 sameAs 3206421422 @default.
W3206421422 citedByCount "0" @default.
W3206421422 crossrefType "journal-article" @default.
W3206421422 hasAuthorship W3206421422A5006031044 @default.
W3206421422 hasAuthorship W3206421422A5017155583 @default.
W3206421422 hasAuthorship W3206421422A5017711682 @default.
W3206421422 hasAuthorship W3206421422A5021417774 @default.
W3206421422 hasAuthorship W3206421422A5024338340 @default.
W3206421422 hasAuthorship W3206421422A5029849168 @default.
W3206421422 hasAuthorship W3206421422A5030660777 @default.
W3206421422 hasAuthorship W3206421422A5037227971 @default.
W3206421422 hasAuthorship W3206421422A5039293124 @default.
W3206421422 hasAuthorship W3206421422A5045980264 @default.
W3206421422 hasAuthorship W3206421422A5050993312 @default.
W3206421422 hasAuthorship W3206421422A5052012397 @default.
W3206421422 hasAuthorship W3206421422A5058683482 @default.
W3206421422 hasAuthorship W3206421422A5059328493 @default.
W3206421422 hasAuthorship W3206421422A5060153507 @default.
W3206421422 hasAuthorship W3206421422A5072622243 @default.
W3206421422 hasAuthorship W3206421422A5075306675 @default.
W3206421422 hasAuthorship W3206421422A5078489750 @default.
W3206421422 hasBestOaLocation W32064214221 @default.
W3206421422 hasConcept C126322002 @default.
W3206421422 hasConcept C13280743 @default.
W3206421422 hasConcept C176809094 @default.
W3206421422 hasConcept C203014093 @default.
W3206421422 hasConcept C205649164 @default.
W3206421422 hasConcept C2776042228 @default.
W3206421422 hasConcept C2776804153 @default.
W3206421422 hasConcept C2777714996 @default.
W3206421422 hasConcept C2779824493 @default.
W3206421422 hasConcept C3018587741 @default.
W3206421422 hasConcept C71924100 @default.
W3206421422 hasConceptScore W3206421422C126322002 @default.
W3206421422 hasConceptScore W3206421422C13280743 @default.
W3206421422 hasConceptScore W3206421422C176809094 @default.
W3206421422 hasConceptScore W3206421422C203014093 @default.
W3206421422 hasConceptScore W3206421422C205649164 @default.
W3206421422 hasConceptScore W3206421422C2776042228 @default.
W3206421422 hasConceptScore W3206421422C2776804153 @default.
W3206421422 hasConceptScore W3206421422C2777714996 @default.
W3206421422 hasConceptScore W3206421422C2779824493 @default.
W3206421422 hasConceptScore W3206421422C3018587741 @default.
W3206421422 hasConceptScore W3206421422C71924100 @default.
W3206421422 hasIssue "4" @default.
W3206421422 hasLocation W32064214221 @default.
W3206421422 hasOpenAccess W3206421422 @default.
W3206421422 hasPrimaryLocation W32064214221 @default.
W3206421422 hasRelatedWork W2980793908 @default.
W3206421422 hasRelatedWork W2981190950 @default.
W3206421422 hasRelatedWork W3098563625 @default.
W3206421422 hasRelatedWork W3157514869 @default.
W3206421422 hasRelatedWork W3205058914 @default.
W3206421422 hasRelatedWork W3206421422 @default.
W3206421422 hasRelatedWork W3207483755 @default.
W3206421422 hasRelatedWork W4300002496 @default.
W3206421422 hasRelatedWork W4367599627 @default.
W3206421422 hasRelatedWork W4367604293 @default.
W3206421422 hasVolume "160" @default.
W3206421422 isParatext "false" @default.
W3206421422 isRetracted "false" @default.
W3206421422 magId "3206421422" @default.
W3206421422 workType "article" @default.